% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Jung:143228,
author = {A. Y. Jung$^*$ and X. Cai$^*$ and K. Thoene and N. Obi and
S. Jaskulski$^*$ and S. Behrens$^*$ and D. Flesch-Janys and
J. Chang-Claude$^*$},
title = {{A}ntioxidant supplementation and breast cancer prognosis
in postmenopausal women undergoing chemotherapy and
radiation therapy.},
journal = {The American journal of clinical nutrition},
volume = {109},
number = {1},
issn = {1938-3207},
address = {Oxford},
publisher = {Oxford University Press},
reportid = {DKFZ-2019-00827},
pages = {69 - 78},
year = {2019},
abstract = {There is a paucity of information on the prevalence of
dietary supplement use in breast cancer survivors. Only a
few studies have examined the impact of dietary supplements,
particularly antioxidants, on breast cancer prognosis and
the results are inconclusive.We examined pre- and
postdiagnosis use of supplements in postmenopausal breast
cancer survivors in Germany and investigated associations
between postdiagnosis use of antioxidants and other
supplements, and prognosis (total and breast cancer
mortality, and recurrence-free survival) both overall and in
women who received chemotherapy and radiation therapy.Data
from 2223 postmenopausal women diagnosed with nonmetastatic
breast cancer from the population-based Mamma Carcinoma Risk
Factor Investigation (MARIE) study were used. Women were
interviewed at recruitment in 2002-2005 and again in 2009
and followed-up until 30 June 2015. Multivariate Cox
regression analysis was used to estimate HRs and
corresponding $95\%$ CIs.Pre- and postdiagnosis supplement
use was reported by $36\%$ and $45\%$ of the women,
respectively. There were 240 deaths (134 from breast cancer)
and 200 breast cancer recurrences after a median follow-up
time of 6.0 y after the 2009 re-interview. After adjusting
for relevant confounders, concurrent antioxidant use with
chemotherapy or radiation therapy among 1940 women was
associated with increased risk of total mortality (HR: 1.64;
$95\%$ CI: 1.01, 2.66) and worsened recurrence-free survival
(HR: 1.84; $95\%$ CI: 1.26, 2.68). Overall postdiagnosis
supplement use was not associated with breast cancer
prognosis.Antioxidant use during chemotherapy or radiation
therapy was associated with worsened breast cancer prognosis
in postmenopausal women. There was no overall association
between postdiagnosis supplement use and breast cancer
prognosis. Results from our study align with the current
recommendation to possibly avoid the use of antioxidants
during chemotherapy or radiation therapy.},
cin = {C020},
ddc = {570},
cid = {I:(DE-He78)C020-20160331},
pnm = {313 - Cancer risk factors and prevention (POF3-313)},
pid = {G:(DE-HGF)POF3-313},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:30668630},
doi = {10.1093/ajcn/nqy223},
url = {https://inrepo02.dkfz.de/record/143228},
}